Network meta-analysis comparing the efficacy of biologic treatments for achieving complete resolution of nail psoriasis

Background: Nail psoriasis (NP) is common and of high importance in patients with psoriasis. Complete resolution of NP at week 24‒26 is an unambiguous nail outcome accessible for indirect treatment comparison of biologics. Objective: To evaluate the comparative efficacy of approved biologics in achieving complete resolution of NP at week 24‒26. Methods: A network meta-analysis (NMA) was conducted to indirectly compare the efficacy of six biologics in achieving complete resolution of NP at week 24‒26 in patients with moderate-to-severe psoriasis and concomitant NP. Complete resolution of NP was defined as a score of zero on the Nail Psoriasis Severity Index (NAPSI), modified NAPSI (mNAPSI) or Physician’s Global Assessment of Fingernails (PGA-F). Results: The probability of achieving complete resolution of NP was highest for ixekizumab (46.5%; 95% credibility interval [CrI] 35.1‒58.0; Surface Under the Cumulative RAnking curve [SUCRA] 97%), followed by brodalumab (37.0%; 17.0‒61.0; 79%), adalimumab (28.3%; 24.4‒32.4; 62%), guselkumab (27.7%; 21.1‒35.1; 58%), ustekinumab (20.8%; 10.2‒35.2; 37%), and infliximab (0.8%; 0.0‒8.9; 17%). Conclusion: In patients with moderate-to-severe psoriasis and concomitant NP, ixekizumab has the greatest likelihood among approved biologics of achieving complete resolution of NP at week 24‒26. Findings should be interpreted carefully because of inherent study limitations.

Conrad, CurdinLausanne University Hospital (författare)
Kristensen, Lars ErikLund University,Lunds universitet,Reumatologi och molekylär skelettbiologi,Sektion III,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Rheumatology,Section III,Department of Clinical Sciences, Lund,Faculty of Medicine,Copenhagen University Hospital(Swepub:lu)med-lkr (författare)
Smith, Saxon D.University of Sydney (författare)
Puig, LuisAutonomous University of Barcelona (författare)
Rich, PhoebeOregon Health & Science University (författare)
Sapin, ChristopheEli Lilly and Company (författare)
Holzkaemper, ThorstenEli Lilly and Company (författare)
Koppelhus, UffeEli Lilly and Company (författare)
Schuster, ChristopherEli Lilly and Company,Medical University of Vienna (författare)
University Medical Center Hamburg-EppendorfLausanne University Hospital (creator_code:org_t)

Ingår i:Journal of Dermatological Treatment: Informa UK Limited33:3, s. 1652-16600954-66341471-1753

Av författaren/redakt...: Reich, Kristian; Conrad, Curdin; Kristensen, Lars ...; Smith, Saxon D.; Puig, Luis; Rich, Phoebe; visa fler...; Sapin, Christoph ...; Holzkaemper, Tho ...; Koppelhus, Uffe; Schuster, Christ ...; visa färre...

Om ämnet

MEDICIN OCH HÄLSOVETENSKAP: MEDICIN OCH HÄLS ...; och Klinisk medicin; och Dermatologi och ...

MEDICIN OCH HÄLSOVETENSKAP: MEDICIN OCH HÄLS ...; och Klinisk medicin; och Reumatologi och ...

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.